Pages
Products
CAG-FLEX-GCaMP6m AAV (Serotype 9)

CAG-FLEX-GCaMP6m AAV (Serotype 9)

Cat.No. :  AAB0023

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAB0023
Description Premade AAV particles in serotype 9 containing Cre-dependent GCaMP6m under the control of a CAG promoter.
Serotype AAV Serotype 9
Tag GCaMP6m
Product Type Adeno-associated virus particles
Biosensor GCaMP6m-Improved SNR, intermediate kinetics; Green indicator
Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

One of the long-standing goals of gene therapy is to deliver vectors directly from the circulatory system to diseased organs. Efforts to achieve this goal using recombinant adeno-associated virus (AAV) vectors have been hampered by the fact that most vectors end up in the liver after systemic delivery. In addition, tissue-specific barriers, such as the blood-brain barrier (BBB), can restrict vector access from the blood to certain organs. AAV9, originally isolated by James Wilson and colleagues, is one of a lineage of AAVs that includes more than 100 new serotypes that remain poorly characterized. Of these, AAV9 stands out. Vectors carrying capsids from these serotypes are approximately 100 times more efficient than AAV2 at delivering transduction to rodent muscle, liver, and lung. A major reason for the growing popularity of AAV9 in the treatment of neurological diseases is its superior ability to cross the BBB. The prospect of delivering therapeutic genes directly to the brain via the vasculature promises a more direct approach to treating a variety of neurological diseases, especially infantile genetic diseases that affect the structure and function of large areas of the brain. Because AAV9 also effectively transduces spinal motor neurons and dorsal root ganglia after systemic delivery, this vector may merit accelerated clinical development for the treatment of diseases that also affect spinal cord structure and function, such as amyotrophic lateral sclerosis, neuropathic pain, spinal cord injury, and certain ataxias.

Social behavior is essential for human connection and belonging, and often influences disorders such as autism spectrum disorder (ASD). The mesoaccumbens pathway (VTA and NAc) plays a key role in social behavior and has been implicated in ASD. Here, researchers used the Shank3-deficient rat model to examine the effects of Shank3 mutations on the midbrain nucleus accumbens pathway during behavior. The results showed that Shank3-deficient rats displayed atypical social interactions and had difficulty adjusting behavior based on reward value, which was associated with altered neuronal activity in VTA dopaminergic and GABAergic neurons and reduced dopamine release in the NAc. Furthermore, the study demonstrated that manipulation of VTA neuronal activity normalized this behavior, providing insight into the effects of Shank3 mutations on social reward and behavior and identifying potential neural pathways for intervention.

To investigate the effects of Shank3 mutations on the neural activity of VTA-GABA neurons during social interactions, the researchers injected the VTA with AAV9-CAG-FLEX-GCaMP6m virus, which is responsible for expressing GCaMP6 in a Cre-dependent manner, and rAAV-hVGAT1-Cre-WPRE-hGH polyA virus, which expresses Cre recombinase under the control of the vesicular GABA transporter (vGAT) promoter, which is commonly used to target GABAergic neurons60 (Figures 1A and 1B). Recordings showed that while WT rats showed a slight increase in VTA-GABA activity when approaching social stimuli, both Shank3-Het and Shank3-KO rats showed significantly higher increases in VTA-GABA activity (Figures 1C-E). In the social vs. food task (Figure 1F), the researchers observed a similar trend of increased VTA-GABA activity only when rats approached social stimuli but not food stimuli (Figure 1G-I and Figure 1J-L, respectively). Taken together, these findings suggest that Shank3-deficient rats exhibit abnormal increases in VTA-GABA neural activity that are specific to social interactions and not universal to all stimuli.

Shank3-deficient rats show abnormal increase in VTA-GABA neural activity during social interaction.Figure 1. Shank3-deficient rats show abnormal increase in VTA-GABA neural activity during social interaction. (Barbier M, et al., 2023)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Neuronal Specificity

I’m impressed by the neuronal specificity of the Syn-FLEX-NES-jRCaMP1a AAV (Serotype 8). It precisely targets our cell types of interest, reducing off-target effects and improving the quality of our experiments.

United Kingdom

05/08/2023

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction